MissionIR Articles
Original content written and distributed as part of our ongoing relationships.
-
PaxMedica Inc. (NASDAQ: PXMD) PRV Sale Prospects Strengthened by Recent Industry Developments
PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has set its sights on an exciting potential opportunity. With the engagement of Bourne Partners, a prominent financial services firm specializing…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) CEO Provides Shareholder Update
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today shared an open letter to shareholders from CEO David Michery, providing updates on various matters and company initiatives. In the letter, Michery highlights several…
-
MissionIRNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD), Bourne Partners to Collaborate in Evaluating Future Monetization of Potential PRV
PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, is working with leading financial services firm Bourne Partners. Bourne Partners specializes in the pharma, pharma services and consumer health spaces. According…
-
MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the…
-
D-Wave Quantum Inc. (NYSE: QBTS) and Satispay Build Quantum Hybrid Application Designed to Optimize Customer Rewards Initiatives
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, recently announced that it is working with Satispay, the leading Italian fintech unicorn…
-
SenesTech Inc. (NASDAQ: SNES) Webcast at Lytham Fall Investor Conference Highlights Company’s Innovation and Growth with New Solution for Rodent Control
Rodent control innovator SenesTech (NASDAQ: SNES) is delivering a new method of administering its unique, patented contraceptive technology that serves as a form of birth control in both male and female rats, making SenesTech’s solution…
-
MissionIRNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Now Taking Orders for Evolve(TM) Soft Bait
SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, announced that it is now taking orders from commercial customers for Evolve(TM) Soft Bait (“Evolve(TM)”), a solution designed to reduce fertility in…
-
MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general counsel and chief strategy officer, will be providing…
-
MissionIRNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Reports on Progress at Bolivian Iska Iska Project
Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine-development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, has completed a metallurgical drill program at its Iska…
-
SuperCom Ltd. (NASDAQ: SPCB) Eyes the Growing World Market for Domestic Violence Offender Monitoring Solutions
SuperCom (NASDAQ: SPCB), a global provider of traditional and digital identity solutions offering advanced safety, identification, and security products and solutions to governments, is constantly pushing the envelope with innovation and exploring new markets for…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q3 2023 Financial Report, Reports Possible Adjustment of Facility Terms by EIB
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, is reporting on its financial results for the…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Third Quarter 2023 Results Conference Call
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, announced that it will hold a conference call on Tuesday,…
-
MissionIRNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Reports on Voting at Annual Meeting
Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine-development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, is reporting on the voting held during its annual…
-
MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Acquires Research Assets to Accelerate PAX-101 NDA Submission
PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, today announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (“RLS”). The assets were previously dedicated to…
-
Freight Technologies Inc. (NASDAQ: FRGT) Taking Part in the Trucking Industry’s Ongoing Paradigm Shift with Its Fr8App Platform
Freight brokers are changing the face of the trucking industry, upending decades-old preferences that previously forced them to operate on the fringes. Brokers now handle over 20% of all trucking freight, up from 6% in…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows List of Licensed Partners Following Exclusive Collaboration and License Agreement with SulfoSyn
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its latest global, exclusive license to SulfoSyn Limited to use its patented DehydraTECH(TM) technology. This license will allow SulfoSyn to use Lexaria’s…
-
MissionIRNewsBreaks – Electronic Servitor Publication Network Inc. (XESP) Announces Participation at Emerging Growth Conference
Electronic Servitor Publication Network (OTCQB: XESP), a digital engagement company and market disruptor, today announced that it has been invited to present at the Emerging Growth Conference on Nov. 1, 2023. The live, interactive online…
-
MissionIRNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Extends Collaboration with Romanian Government on Pivotal EM Initiative
SuperCom Ltd. (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT and cybersecurity sectors, today announced, together with its local partner, the receipt of a third order by Romania’s Ministry of Interior,…
-
MissionIRNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on 1-for-17 Reverse Stock Split
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, has released…
-
MissionIRNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Announces Planned Launch of Its Highly Anticipated Wellness Beverage
Safety Shot (NASDAQ: SHOT) today announced the upcoming direct-to-consumer launch of Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Beginning the…
-
SenesTech Inc. (NASDAQ: SNES) Geometrically Increases its Addressable Market with the Addition of Evolve(TM) Soft Bait to its Portfolio
SenesTech (NASDAQ: SNES), a rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats, just announced the launch of its Evolve(TM) Soft Bait (“Evolve”), a minimum-risk solution in…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, will be attending and participating in BIO-Europe,…
-
Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study
Amyotrophic lateral sclerosis (“ALS”), or Lou Gehrig’s disease, is a progressive and degenerative neuromuscular disease that destroys nerve cells known as motor neurons, which control voluntary muscle movement (https://ibn.fm/bgJGu). A fatal neurological disorder, ALS lowers…
-
Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, just announced positive top-line results from its CLEAR MIND Phase 2a clinical trial for treating mild Alzheimer’s disease. Most notably,…
-
MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Secures $5.2M in Private Placement and Preferred Investment Option Offerings
InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that it has closed its offering for the issuance and…
-
MissionIRNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on Publication of Low-Dose Suramin for ASD Research
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, announced that its groundbreaking research will be published in the “Annals of General Psychiatry,” an internationally recognized scientific psychiatry publication. The research was reported in a manuscript titled…
-
PaxMedica Inc.’s (NASDAQ: PXMD) CEO and Corporate Communications Chief Discuss Regulatory Strategy for Lead Drug Candidate and Future Plans in Recent Bell2Bell Podcast Interview
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company specializing in innovative treatments for unmet needs in neurodevelopmental disorders, has recently introduced a groundbreaking regulatory strategy that could potentially pave the way for the approval of its…
-
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Showcase Its Boutique End-to-End CDMO Services at the Premier CPHI Barcelona Event
Scinai Immunotherapeutics (NASDAQ: SCNI), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, will be showcasing its Contract Development and Manufacturing Organization (“CDMO”) services at CPHI Barcelona, a premier three-day event that…
-
MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS), QuantumBasel Announce Two-Year Agreement Extension to Fuel Quantum Commercial Adoption
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services as well as the world’s first commercial supplier of quantum computers, has extended its relationship with QuantumBasel. In addition, according to the…
-
MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Clearing Path to Submit NDA for PAX-101
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, today announced the completion of a type-B meeting with the FDA. During the live meeting, the company discussed positive results of the recent data from its PAX-HAT-301 study…
-
MissionIRNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Request to Continue Listing Is Granted by NASDAQ Hearings Panel
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, was notified by the NASDAQ Hearings Panel that its request to continue listing on the NASDAQ capital market has been granted with two conditions. Those…
-
MissionIRNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Selected by Leading Pharmaceutical Giant for Vital Logistics Operation
Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company offering its custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning and providing a real-time portal for B2B cross-border shipping and domestic shipping within…
-
MissionIRNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Brings Sustainable Solution for Rising Demand in ‘Rattiest Cities’
A recent Fox Business article discussed pest control company Orkin’s annual ranking of the “Top 50 Rattiest Cities,” where Chicago continues to top the list, followed by Los Angeles, New York City, Washington, D.C., and…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Two New Canadian Patents Amid Continued Efforts to Safeguard the Applicability of Its DehydraTECH(TM) Technology in Multiple Jurisdictions and Sectors
Lexaria Bioscience (NASDAQ: LEXX) is a global innovator and biotechnology company focused on developing technology that enhances the bioavailability of multiple fat-soluble active molecules and active pharmaceutical ingredients (“APIs”). The company’s flagship technology is the patented…
-
MissionIRNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Schedules Q3 2023 Earnings Call
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services, has announced plans to report on its third-quarter financial results for the period ended Sept. 30, 2023. The company will issue its…
-
MissionIRNewsBreaks – Safety Shot (NASDAQ: SHOT) Granted Second U.S. Patent for JW-700 Treatment Designed for $1.5B Hair-Growth Market
Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, announced a “significant milestone” in its development of treatments for androgenetic alopecia, or hair loss: the granting of a second U.S. patent issued for JW-700,…
-
MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters Agreements for Private Placement, Preferred Investment Options
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, has entered into a definitive agreement for the issue and sale of more than 3…
-
Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company on a mission to transform the treatment of neurodegenerative diseases, recently announced that its wholly-owned subsidiary Clene Nanomedicine Inc., in collaboration with Columbia University and Synapticure, has…
-
MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Advance INM-901 Following Positive Proof-of-Concept Results
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced its selection of a lead Alzheimer’s disease drug candidate, named INM-901, following positive…
-
MissionIRNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, is featured in a recent NetworkNewsAudio (“NNA”)…
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option